Active Cells, Biochemistry & Physiology Infection & Immunity

Role of Toxoplasma mitochondrial respiration and ATP synthesis in parasite survival, virulence, and persistence – a complex story!

In plain English

AI plain-English summary

Toxoplasma parasites hijack the energy-making machinery inside their own cells in a way that is fundamentally different from how human cells do it, and this difference could be their Achilles’ heel. The parasite that causes toxoplasmosis infects roughly one-third of the global population and can remain dormant in the body for life. In people with weakened immune systems, the infection can be fatal. Existing drugs have serious side effects, and resistance is emerging. The parasite’s mitochondrial energy pathway—its version of a cellular power plant—is built from unusual protein subunits not found in humans, making it a promising drug target. But researchers do not yet understand how these unique parts work, how they help the parasite survive inside animals, or why they make the parasite more sensitive to certain inhibitors. This project aims to map out exactly how the parasite’s energy pathway functions, both in active infection and in the dormant bradyzoite stage that resists treatment. If successful, the work will reveal the molecular basis for drug sensitivity and provide a blueprint for designing new compounds that target the parasite without harming human cells. The findings could also apply to malaria, another disease caused by a related parasite.

View original technical description
Apicomplexan parasites cause severe diseases, including toxoplasmosis and malaria. Toxoplasmosis can be fatal in immunocompromised patients and persists for life. Drug resistance and side effects necessitate new drugs. The apicomplexan mitochondrial electron transport chain (mETC) and ATP synthase pathway offers excellent opportunities to develop better drugs, because this pathway is critical for parasite survival and virulence and has striking differences from the human pathway. We recently found that each of the parasite enzymes consists of different subunits and show structural differences from their human parallels(1–3), manifesting in selective sensitivity to inhibitors, e.g the clinically used atovaquone. Yet, the function of the new subunits and how these differences lead to increased drug sensitivity in the parasite are not understood, hindering the development of better drugs. Moreover, some new subunits are essential for virulence in animals, and mETC inhibitors further kill bradyzoites, the persistent life- stage. Yet the pathway’s role during animal infection and bradyzoites biology remain largely understudied. This work will generate mechanistic understanding of divergent aspects of apicomplexan mETC and ATP synthase, reveal their role during animal infection, and develop studies of their role during persistence. We will further elicit inhibitor mode-of-action, together informing drug development for toxoplasmosis and potentially malaria.

View the original record at the funder ↗

Researchers

Alexander Mühleip (EPMC Awardee)Anita Koshy (EPMC Awardee)Lilach Sheiner (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

Elucidating the structure and function of the divergent and essential cytochrome bc1 complex in apicomplexan parasites
Characterization of critical differences between human and parasite respiratory complex II
Identification and functional characterization of proteins of the mitochondrial tRNA import pathway of Toxoplasma gondii
Exploring sulfur metabolism in the deadly intracellular parasite Toxoplasma gondii
Power Struggles: How parasite mitochondria control infection in animals

Original classification

Discovery Award

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.